https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2005-01-01 / Immunol. Invest. 2005;34(3):259-72
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2005-01-01 / Immunol. Invest. 2005;34(3):259-722005-01-01 00:00:002019-02-15 09:17:48An important role for granulocytes in the thermal regulation of colon tumor growth
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-12-17 / Cancer Immunol. Immunother. 2005 Jul;54(7):663-70
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-12-17 / Cancer Immunol. Immunother. 2005 Jul;54(7):663-702004-12-17 00:00:002019-02-15 09:17:04Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-12-01 / Gynecol. Oncol. 2004 Dec;95(3):680-5
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-12-01 / Gynecol. Oncol. 2004 Dec;95(3):680-52004-12-01 00:00:002019-02-15 08:35:32Phase II study of carboplatin and whole body hyperthermia (WBH) in recurrent and metastatic cervical cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-12-01 / J. Urol. 2004 Dec;172(6 Pt 2):2532-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-12-01 / J. Urol. 2004 Dec;172(6 Pt 2):2532-82004-12-01 00:00:002019-02-15 09:24:22Dendritic cell based vaccines: progress in immunotherapy studies for prostate cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-12-01 / J. Hepatol. 2004 Dec;41(6):999-1007
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-12-01 / J. Hepatol. 2004 Dec;41(6):999-10072004-12-01 00:00:002019-02-15 09:11:52Immunoregulation of dendritic and T cells by alpha-fetoprotein in patients with hepatocellular carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-12-01 / Minerva Ginecol 2004 Dec;56(6):515-27
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-12-01 / Minerva Ginecol 2004 Dec;56(6):515-272004-12-01 00:00:002004-12-01 00:00:00Current approaches in ovarian cancer vaccines
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-11-28 / Nat. Med. 2004 Dec;10(12):1359-65
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-11-28 / Nat. Med. 2004 Dec;10(12):1359-652004-11-28 00:00:002019-02-15 09:15:21Therapeutic dendritic-cell vaccine for chronic HIV-1 infection
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-11-01 / Br. J. Cancer 2004 Nov;91(9):1656-62
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-11-01 / Br. J. Cancer 2004 Nov;91(9):1656-622004-11-01 00:00:002021-11-15 15:38:39Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-11-01 / Cancer Res. 2004 Nov;64(21):8022-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-11-01 / Cancer Res. 2004 Nov;64(21):8022-82004-11-01 00:00:002019-02-15 08:50:25Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-11-01 / Cancer Res. 2004 Nov;64(21):8057-61
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-11-01 / Cancer Res. 2004 Nov;64(21):8057-612004-11-01 00:00:002020-06-23 09:39:52Antitumor vaccination in patients with head and neck squamous cell carcinomas with autologous virus-modified tumor cells
